HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Status:
Enrolling by invitation
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a single center, single arm, phase II, prospective study to evaluate the efficacy and
safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with PD-1 inhibitor
immunotherapy Toripalimab and Tyrosine Kinase Inhibitor Donafenib in patients with advanced
biliary tract cancer.